drugset
drugset / Trial / NCT05934955

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)

NCT05934955 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1839100 in healthy male subjects following oral administration of single rising doses.

Timeline

Start
2023-07-13
Primary completion
2023-09-25
Completion
2023-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1839100 Unknown — Oral

Indications

No indication recorded.